ROBO2 and Hepatic fibrosis: sTREM‐1 is a therapeutic target for liver fibrosis, and the advent of short peptide inhibitors42, 43, 44 will greatly increase the possibility of clinical transformation of the sTREM‐1‐Robo2 axis.